Comparative efficacy and safety of vonoprazan versus esomeprazole-based high-dose dual therapies for first-line <i>Helicobacter pylori</i> eradication: a randomized controlled trial.

Ther Adv Gastroenterol · 2025 · PMC12450270 · PMID 40984972

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Notably, VA-HDDT attained a numerically higher PP eradication rate (93.0%) compared with EA-HDDT (84.5%), although this difference did not reach statistical significance, likely due to the limited sample size.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Comparative efficacy and safety of vonoprazan versus esomeprazole-based high-dose dual therapies for first-line &lt;i&gt;Helicobacter pylori&lt;/i&gt; eradication: a randomized controlled trial.

The sentences

Comparative efficacy and safety of vonoprazan versus esomeprazole-based high-dose dual therapies for first-line <i>Helicobacter pylori</i> eradication: a randomized controlled trial.